Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
UNLABELLED: The prostate stem cell antigen (PSCA) is a glycosylphosphatidyl-inositol (GPI)-linked cell surface antigen expressed in normal prostate and overexpressed in the majority of prostate cancers and correlates with tumor grade and disease stage. Because PSCA has been described to be up-regulated in pancreatic cancer, the purpose was to evaluate the expression of PSCA in human pancreatic cancer. Furthermore, the therapeutic efficacy of a monoclonal anti-PSCA antibody in an in vivo pancreatic cancer model was determined. METHODS: The expression of PSCA in human pancreatic cancer tissues was determined and compared with chronic pancreatitis and normal pancreas by quantitative reverse transcriptase-polymerase chain reaction. Therapeutic efficacy of the monoclonal anti-PSCA antibody 1G8 was examined in Capan-1 pancreatic tumors grown as subcutaneous grafts in athymic nude mice. RESULTS: PSCA was strongly up-regulated in human pancreatic cancer compared with chronic pancreatitis and normal pancreas. In addition, the PSCA protein was expressed on the cell surface of pancreatic cancer cells. Treatment with 1G8 significantly reduced tumor growth initiation in an in vivo pancreatic cancer xenograft model. In addition, antibody treatment of established tumors reduced tumor progression. CONCLUSIONS: These results show a potential therapeutic role for anti-PSCA antibodies in the treatment of pancreatic cancer. Furthermore, PSCA might serve as a novel marker in the diagnosis of pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Cited by
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy
Yu, M. K., Park, J., & Jon, S. (2012) · Theranostics · doi:10.7150/thno.3463 · Cited by 883
Mohammed, S., Sukumaran, S., Bajgain, P., Watanabe, N., Heslop, H. E., Rooney, C. M., Brenner, M. K., Fisher, W. E., Leen, A. M., & Vera, J. F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.016 · Cited by 281
Engineered T cells for pancreatic cancer treatment
Katari, U. L., Keirnan, J. M., Worth, A. C., Hodges, S. E., Leen, A. M., Fisher, W. E., & Vera, J. F. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00344.x · Cited by 61
Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer
Tummers, W. S., Willmann, J. K., Bonsing, B. A., Vahrmeijer, A. L., Gambhir, S. S., & Swijnenburg, R.-J. (2018) · Pancreas · doi:10.1097/mpa.0000000000001075 · Cited by 50
Metadata
- Authors
- Wente, M. N., Jain, A., Kono, E., Berberat, P. O., Giese, T., Reber, H. A., Friess, H., B??chler, M. W., Reiter, R. E., & Hines, O. J.
- Venue
- Pancreas
- Published
- 2005-08
- Volume
- 31
- Issue
- 2
- Pages
- 119-125
- ISSN
- 0885-3177 (ISSN-L)
- OpenAlex
- W2021749518
- Cited by
- 94
- References
- 1
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer. https://app.cochat.ai/papers/10.1097/01.mpa.0000173459.81193.4d
- The paper
- Wente, M. N., Jain, A., Kono, E., Berberat, P. O., Giese, T., Reber, H. A., Friess, H., B??chler, M. W., Reiter, R. E., & Hines, O. J. (2005). Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer. Pancreas. https://doi.org/10.1097/01.mpa.0000173459.81193.4d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.